Biomarin Pharmaceutical Inc to Discuss FDA Approval for VOXZOGO™ Call Transcript
Please go ahead, JJ.
Okay. So welcome, everyone, and thank you for joining us on today's call. We are, as you can imagine, very pleased to share the news of FDA's approval of VOXZOGO for children, ages 5 and older. I want to thank the FDA, the families who participated in our cable programs, our investigators and advocates and especially my colleagues in clinical development and regulatory affairs at BioMarin who have all contributed to this important day for children with achondroplasia. VOXZOGO's approval in Europe in August and in the United States today marks a significant milestone for BioMarin. The teams have shown tremendous persistence and diligence with a single-mind focus on getting VOXZOGO approved for the benefits of families seeking a treatment option for achondroplasia. Perseverance is part of our company's culture, and it is achievers like today's that today's approval of VOXZOGO that keeps us motivated
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
